Hypoplastic MDS is a variant of Myelodysplastic Syndrome characterized by bone marrow hypoplasia (hypocellular marrow), typically defined by a low percentage of marrow blasts ($<5%$).
Key Clinical Considerations
- Pathophysiology & Treatment Model: Because its biology overlaps with immune-mediated marrow failure, hypoplastic MDS is managed similarly to aplastic anemia.
- Preferred Therapy: The standard treatment is immunosuppressive therapy (IST), specifically the combination of equine anti-thymocyte globulin (ATG) and cyclosporine.
- Patient Selection: IST is most effective in patients who are younger (<60 years old), have a shorter duration of transfusion dependence, and possess normal cytogenetics.
- Pharmacist Pearl: For patients with hypoplastic MDS, erythropoiesis-stimulating agents (ESAs) like epoetin are considered inappropriate; these patients should proceed directly to IST if treatment is indicated.